Veregen Patent Expiration

Veregen is a drug owned by Ani Pharmaceuticals Inc. It is protected by 5 US drug patents filed from 2013 to 2019. Out of these, 2 drug patents are active and 3 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 02, 2026. Details of Veregen's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5968973 Method for treating hyperplasia
Apr, 2017

(7 years ago)

US5795911 Composition for treating Condyloma acuminata
Oct, 2020

(3 years ago)

US10434059 Medicament for the treatment of viral skin and tumour diseases
Nov, 2022

(1 year, 7 months ago)

US9770406 Medicament for the treatment of viral skin and tumour diseases
Jul, 2025

(11 months from now)

US7858662 Medicament for the treatment of viral skin and tumour diseases
Oct, 2026

(2 years from now)


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Veregen and ongoing litigations to help you estimate the early arrival of Veregen generic.

Veregen's Litigations

Veregen has been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Sep 08, 2015, against patent number US9770406. The petitioner , challenged the validity or infringement of this patent, with Yunik Chang et al as the respondent. Click below to track the latest information on how companies are challenging Veregen's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US9770406 September, 2015 Decision Yunik Chang et al

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Veregen is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Veregen's family patents as well as insights into ongoing legal events on those patents.

Veregen's family patents

Veregen has patent protection in a total of 21 countries. It's US patent count contributes only to 15.6% of its total global patent coverage. 14 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Veregen.

Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?


Thank you for your response 🥳

Generic Launch

Generic Release Date:

Veregen's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 02, 2026 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Veregen Generics:

There are no approved generic versions for Veregen as of now.

About Veregen

Veregen is a drug owned by Ani Pharmaceuticals Inc. It is used for treating genital warts. Veregen uses Sinecatechins as an active ingredient. Veregen was launched by Ani Pharms in 2006.

Market Authorisation Date:

Veregen was approved by FDA for market use on 31 October, 2006.

Active Ingredient:

Veregen uses Sinecatechins as the active ingredient. Check out other Drugs and Companies using Sinecatechins ingredient


Veregen is used for treating genital warts.


Veregen is available in ointment form for topical use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
15% OINTMENT Prescription TOPICAL